Business Description
Chordia Therapeutics is a Japanese biotechnology company founded in 2017 and headquartered in Fujisawa, focused on developing new medicines to fight cancer. The company's approach centers on correcting abnormal RNA activity within cancer cells, a mechanism that drives tumor growth. Its pipeline includes several drug candidates at various stages of development, with its lead compound CTX-712 currently being tested in early-stage human trials for patients with hard-to-treat cancers.
